产品
编 号：F050454
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 1159266-37-1
产品详情
生物活性：
Mogamulizumab (KW-0761) is a recombinant anti-CCR4 monoclonal antibody (MAb). Mogamulizumab can eliminate tumor cells by antibody-dependent cellular cytotoxicity (ADCC). Mogamulizumab can be used in the research of cancers, adult T-cell leukemia/lymphoma (ATLL), cutaneous T-cell lymphoma (CTCL).
体内研究：
Mogamulizumab (1 mg/kg, i.p., twice per week for 4 weeks) together with PBMC transplantation inhibits the growth of EBV-positive NK-cell lymphomas in a murine xenograft model.Mogamulizumab (0.1 mg/kg, i.v., every other day) together with canine PBMCs (every fourth day)), inhibits tumor growth in canine bladder cancer-engrafted mouse model.Mogamulizumab (0.01-1 mg/kg, i.v.) reduces circulating CD4+CCR4+ T cells, with no adverse effect in dogs.Animal Model:Murine xenograft model, constructed by using the immunodeficient NOG mouse and the EBV-positive NK-cell lymphoma cell line (SNK6)
Dosage:1 mg/kg
Administration:Intraperitoneal injection (i.p.), together with PBMC transplantation; twice per week for 4 weeks.
Result:Suppressed Tumor growth with vacuolar degeneration.
体外研究：
Mogamulizumab (10 μg/mL, 24 h) induces ADCC activity against CCR4-positive cell lines (SNT8, SNT16, SNK6, and KAI3) in the presence of PBMCs.Mogamulizumab (10 μg/mL, 3 days) reduces the human T-lymphotropic virus type 1 (HTLV-1) proviral load and inhibits spontaneous proliferation in PBMCs from patients with HTLV-1–associated myelopathy/tropical spastic paraparesis (HAM/TSP).Mogamulizumab (1 μg/mL, 5 days) eliminates the CD4+CCR4+ T cells in cultured PBMCs from patients with HAM/TSP.
Mogamulizumab (KW-0761) is a recombinant anti-CCR4 monoclonal antibody (MAb). Mogamulizumab can eliminate tumor cells by antibody-dependent cellular cytotoxicity (ADCC). Mogamulizumab can be used in the research of cancers, adult T-cell leukemia/lymphoma (ATLL), cutaneous T-cell lymphoma (CTCL).
体内研究：
Mogamulizumab (1 mg/kg, i.p., twice per week for 4 weeks) together with PBMC transplantation inhibits the growth of EBV-positive NK-cell lymphomas in a murine xenograft model.Mogamulizumab (0.1 mg/kg, i.v., every other day) together with canine PBMCs (every fourth day)), inhibits tumor growth in canine bladder cancer-engrafted mouse model.Mogamulizumab (0.01-1 mg/kg, i.v.) reduces circulating CD4+CCR4+ T cells, with no adverse effect in dogs.Animal Model:Murine xenograft model, constructed by using the immunodeficient NOG mouse and the EBV-positive NK-cell lymphoma cell line (SNK6)
Dosage:1 mg/kg
Administration:Intraperitoneal injection (i.p.), together with PBMC transplantation; twice per week for 4 weeks.
Result:Suppressed Tumor growth with vacuolar degeneration.
体外研究：
Mogamulizumab (10 μg/mL, 24 h) induces ADCC activity against CCR4-positive cell lines (SNT8, SNT16, SNK6, and KAI3) in the presence of PBMCs.Mogamulizumab (10 μg/mL, 3 days) reduces the human T-lymphotropic virus type 1 (HTLV-1) proviral load and inhibits spontaneous proliferation in PBMCs from patients with HTLV-1–associated myelopathy/tropical spastic paraparesis (HAM/TSP).Mogamulizumab (1 μg/mL, 5 days) eliminates the CD4+CCR4+ T cells in cultured PBMCs from patients with HAM/TSP.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备